INTRO: Samsung has started rolling out the ECG heart monitoring feature to its Galaxy Watch 3 and Galaxy Watch Active 2 within the US after receiving clearance from the US Food and Drug Administration (FDA). According to Samsung, the ‘ECG Monitor’ feature are going to be a part of the Samsung Health Monitor app, enabling users to see for cardiac rhythm irregularities and determine if they have signs of atrial fibrillation, or AFib.
In a politician handout announcing the rollout of the new feature, the corporate said: “Beginning September 23, users will have access to yet one more next-generation feature, as on-demand electrocardiogram (ECG) readings come to Galaxy Watch3 and Galaxy Watch Active2. This tool recently received clearance from the U.S. Food and Drug Administration (FDA), and can soon be available through the Samsung Health Monitor app when connected to a compatible Galaxy smartphone. The new ECG Monitor app allows users to watch their cardiac rhythm for irregularities, scanning for signs of fibrillation (AFib)”.
It is worth noting that both the watches already had the ECG heart monitoring feature, although, it had been restricted to South Korea due to the delay in regulatory approval within the US. Both the watches are available for purchase in India, and while the Galaxy Watch 3 was just launched last month at a starting price of Rs. 29,990, the Galaxy Watch Active 2 has been on sale since last December.
ECG heart monitoring was originally popularized by Apple when it unrolled the feature to the Apple Watch Series 4 in 2018, making them the primary over-the-counter consumer electronics devices in the US to do so. Since than, variety of other smartwatches and fitness bands, including the Fitbit Sense, Withings ScanWatch and therefore the Amazfit Smartwatch 2, have also incorporated the feature that has often been credited with saving people’s lives round the world.
Image Courtesy: Samsung